Ophthotech Corp  

(Public, NASDAQ:OPHT)   Watch this stock  
Find more results for OPHT
-1.81 (-3.80%)
May 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 45.51 - 48.11
52 week 30.17 - 58.29
Open 47.55
Vol / Avg. 157,500.00/257,259.00
Mkt cap 1.63B
P/E     -
Div/yield     -
EPS -2.96
Shares 34.17M
Beta     -
Inst. own 89%
Jun 4, 2015
Ophthotech Corp Annual Shareholders Meeting - 9:00AM EDT - Add to calendar
May 21, 2015
Ophthotech Corp Annual Shareholders Meeting (Estimated) - 9:00AM EDT - Add to calendar
May 11, 2015
Q1 2015 Ophthotech Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 7, 2015
Ophthotech Corp at Deutsche Bank Health Care Conference - 10:00AM EDT - Add to calendar
Mar 10, 2015
Ophthotech Corp at Barclays Healthcare Conference - Webcast
Feb 23, 2015
Q4 2014 Ophthotech Corp Earnings Call
Feb 23, 2015
Q4 2014 Ophthotech Corp Earnings Release
Feb 12, 2015
Ophthotech Corp at Leerink Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -2130.11% -237.98%
Operating margin -1850.83% -195.14%
EBITD margin - -194.83%
Return on average assets -29.10% -27.42%
Return on average equity -89.08% -61.98%
Employees 72 -
CDP Score - -


1 Penn Plz Fl 19
NEW YORK, NY 10119-0002
United States - Map
+1-212-8458200 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Ophthotech Corporation is a biopharmaceutical company specializing in the development of therapeutics to treat diseases of the eye. The Company�s advanced product candidate is Fovista, which the Company is developing for use in combination with anti-VEGF drugs that represent the current standard of care for the treatment of wet age-related macular degeneration (wet AMD). Wet AMD is a serious disease of the central portion of the retina, known as the macula, which is responsible for detailed central vision and color perception. It is characterized by abnormal new blood vessel formation and growth, referred to as neovascularization, which results in blood vessel leakage, retinal distortion and scar formation. If untreated, the progressive retinal damage results in rapid, irreversible and severe vision loss. Wet AMD is the cause of blindness in patients over the age of 55 in the United States and the European Union.

Officers and directors

David R. Guyer M.D. Chairman of the Board, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Samir C. Patel M.D. Vice Chairman of the Board, President
Age: 53
Bio & Compensation  - Reuters
Evelyn Harrison Chief Operating Officer
Bio & Compensation  - Reuters
Barbara Wood Senior Vice President, General Counsel
Bio & Compensation  - Reuters
Douglas K. Kollmorgen Senior Vice President - Quality Assurance
Bio & Compensation  - Reuters
Harvey N. Masonson M.D. Senior Vice President - Clinical Development
Bio & Compensation  - Reuters
Loni da Silva Senior Vice President - Global Regulatory Affairs
Bio & Compensation  - Reuters
Todd N. Smith Senior Vice President, Chief Commercial Officer
Age: 44
Bio & Compensation  - Reuters
Kathy Galante Vice President of Investor Relations and Corporate Communications, IR Contact Officer
Bio & Compensation  - Reuters
Douglas G. Brooks Ph.D. Vice President - Manufacturing Development
Bio & Compensation  - Reuters